1 Oral Anticoagulants: What s New? Sallie Young, Pharm.D., BCPS (AQ-Cardiology) Clinical Pharmacy Specialist, Cardiology Penn State Hershey Medical Center August 2012
2 Oral Anticoagulant Uses Multiple reasons for oral anticoagulant use VTE prophylaxis Atrial fibrillation/flutter VTE - pulmonary embolism (PE) and/or deep vein thrombosis (DVT) Mechanical heart valves Hypercoagulable states
3 Ideal Characteristics of a New Oral Anticoagulant Multiple indications Oral Once daily dosing No drug interactions No dietary restrictions Antidote availability Inexpensive Predictable response Wide therapeutic window No monitoring required Does not cross placenta or into breast milk
4 Oral Anticoagulation Options Until recently warfarin was only oral anticoagulant available in US Required patient education on Medication and diet consistency Frequency of INR monitoring Use of multiple tablet sizes Alternating doses on different days And much more! Image accessed 3/27/12 from
5 Current Anticoagulation Options Warfarin (Coumadin) Dabigatran (Pradaxa) Approved 2010 Rivaroxaban (Xarelto) Approved 2011 Several others oral anticoagulants are in the later stages of clinical trials Apixaban (Under FDA Review)
6 Clotting Cascade Factor Xa Inhibitors - rivaroxaban Vitamin i K Antagonist (factors 2,7,9, 10, protein c and s) - Warfarin Direct Thrombin Inhibitor - dabigatran
7 Review of Newly Approved Oral Anticoagulants t Dabigatran (Pradaxa ) Rivaroxaban (Xarelto )
8 Dabigatran Etexilate Dabigatran etexilate is a prodrug rapidly converted to the active form, dabigatran, in the body Reversible, direct thrombin inhibitor Inhibits formation of thrombin (factor IIa) therefore preventing formation of fibrin clots Inhibits free and clot bound thrombin as well as thrombin-induced platelet aggregation Lexi-Comp. Accessed 4/6/12.
9 Dabigatran Uses FDA approved indication Reduction in the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillationill i Potential future uses Treatment of venous thromboembolism (VTE, including deep vein thrombosis and pulmonary embolism) Prevention of VTE after orthopedic surgery, such as hip and knee replacement* *Indication in other countries. Lexi-Comp. Accessed 4/6/11.
10 Dabigatran Pharmacokinetics Onset of activity it within 2 hours Low bioavailability (3-7%) Half-life hours No involvement of the CYP450 system however is a p-glycoprotein substrate Cleared renally primarily as glucuronide acid conjugate Prolongs aptt PTTin non-linear fashion Pradaxa Prescribing Information. January 2012.
11 Dabigatran Elimination As renal function declines, the half-life life of the drug increases Renal Function (CrCl) Dabigatran Half Life Normal hours (~80 ml/min) ( hours in elderly) l Mild - Moderate hours impairment (30-50 ml/min) Severe impairment (<30 ml/min) 28 hours Lexi-Comp. Accessed 4/6/12. Stangier et al. Clin Pharmacokinetics 2010;49:
12 Dabigatran AFib Dosing Usual dose: 150 mg orally twice daily Reduce to 75 mg orally twice daily* when CrCl ml/min Consider if CrCl ml/min + p-glycoprotein inhibitors (dronedarone or oral ketoconazole ) Avoid in patients with CCl CrCl <15 ml/min or those on dialysis dil i CrCl ml/min + p-glycoprotein inhibitors *Renal dosing based on pharmacokinetic analysis (not patient data) at time of FDA approval Pradaxa Prescribing Information. January 2012.
13 Dabigatran Monitoring: Routine laboratory testing is not necessary Diet interactions None - vitamin K intake has no effect May be taken with or without food Capsules may not be opened as the drug bioavailability increases by 75%! Should not be administered via feeding tube or with applesauce/pudding Pradaxa Prescribing Information. January 2012.
14 Composition of Dabigatran Dabigatran Etexilate Capsule Capsules Dabigatran Etexilate Pellet Tartaric Acid Core Dabigatran Etexilate Coat Seal Coating Connolly SJ, Ezekowitz MD et al. N Engl J Med. 2009;361: Pradaxa Prescribing Information. Jan 2012.
15 Dabigatran Adverse Effects Bleeding Major bleeding more common than in warfarin patients (1.73% per yr vs. 0.87% per yr) Increased risk as renal function declines Increased gastrointestinal bleeding (dose dependant) d Gastrointestinal upset Incidence higher (35%) than with warfarin (24%) Dyspepsia, abdominal pain, GERD, esophagitis, erosive gastritis, gastrointestinal ulcer Lexi-Comp. Accessed 1/19/11. Connolly SJ et al. N Engl J Med 2010;361:
16 Dabigatran Drug Interactions Does not involve CYP450 enzymes in the liver P-glycoprotein inducers (ex. rifampin) - decrease dabigatran levels/efficacy; PI: Generally Avoid P-glycoprotein inhibitors (ketoconazole, dronedarone) increase dabigatran levels/toxicity Use with other antiplatelet medications, including NSAIDs - increases bleeding risk due to thrombinid induced dplatelet ltltaggregation Should not be used at the same time as warfarin (Coumadin) - therapeutic duplication Lexi-Comp. Accessed 1/19/11.
17 Rivaroxaban (Xarelto) Factor Xa inhibitor Highly selective Exerts activity by blocking the active site on factor Xa Does not require cofactor (such as antithrombin) Inhibits free and clot-associated factor Xa Xarelto Prescribing Information. December 2011.
18 Rivaroxaban Uses FDA Approved Indications Prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE) in patients who are undergoing knee or hip replacement surgery Prevention of stroke or systemic embolism in nonvalvular atrial fibrillation patients Future Use VTE Treatment (PE, DVT)
19 Rivaroxaban Pharmacokinetics Onset of activity it 2-4 4hours Bioavailability >80% for 10 mg, 66% for 20 mg Food increases bioavailability ( 39% mean AUC) Half-life 5-9 hours (elderly 9-12 hrs) Highly and reversibly bound to plasma proteins Undergoes CYP450 metabolism (3A4/5 and 2J2 substrate) but no circulating metabolites P-glycoprotein and ABCG2 substrate Excreted via renal (66%) and non-renal (28%) mechanisms ACCP CHEST Guidelines 9 th Ed. CHEST 2012;141:e44S-e88S.
20 Rivaroxaban for VTE Prophylaxis Prophylaxis of DVT/PE in adult patients undergoing hip and knee replacement surgery CrCl 30 ml/min: 10 mg PO once daily CrCl<30 ml/min or dialysis: Contraindicated Initial dose should be taken at least 6 to 10 hours after surgery once hemostasis has been established Caution with epidural/spinal anesthesia catheter placement/removal or if traumatic puncture Duration: 35 days after THR, 12 days for TKR Xarelto Prescribing Information. December 2011.
21 Rivaroxaban for Atrial Fibrillation Prevention of stroke or systemic embolism in non-valvular atrial fibrillation patients CrCl >50 ml/min: 20 mg po once daily with the evening meal CrCl ml/min: 15 mg po once daily with the evening meal CrCl<15 ml/min or dialysis: CONTRAINDICATED Xarelto Prescribing Information. December 2011.
22 Rivaroxaban Drug Interactions CYP3A4/P-glycoprotein (P-gp) )inducers AVOID, significant in AUC & Cmax; lower efficacy Examples: carbamazepine, phenytoin, rifampin, St. John's wort CYP3A4/P-gp inhibitors AVOID, significant in AUC & Cmax; toxicity Examples: ketoconazole, itraconazole, ritonavir, conivaptan Concomitant use of antiplatelet agents bleeding time Xarelto Prescribing Information. December 2011.
23 Rivaroxaban ADRs Bleeding Similar incidence of major and nonmajor clinically relevant bleeding to warfarin in ROCKET-AF trial Intracranial hemorrhage 0.8% vs. 1.2% in warfarin group (p=0.02) Critical and fatal bleeding significantly less in rivaroxaban patients Non-bleeding: wound secretion, extremity pain, muscle spasm, syncope, pruritis and blisters Xarelto Prescribing Information. December 2011.
24 Converting to and from new oral anticoagulants
25 General Conversion Thoughts Drug clearance should be taken into consideration Hepatic or renal failure? Risk benefit evaluation Bleeding vs. thromboembolism Administration times? Any dose of dabigatran or rivaroxaban would provide VTE prophylaxis (or more)
26 Dabigatran - Warfarin Warfarin to dabigatran Stop warfarin and start dabigatran when INR <2 Dabigatran to warfarin Before stopping dabigatran, start warfarin CrCl 50 ml/min: 3 days CCl3050 CrCl ml/min: 2 days CrCl ml/min: 1 day CrCl <15 ml/min: no recommendation Only check INR after dabigatran stopped for at least 2 days because may affect result Pradaxa Prescribing Information. Jan Lexi-Comp Online. Accessed 3/29/12
27 Dabigatran Parenteral Anticoagulants Parenteral anticoagulant to dabigatran No bridging therapy necessary due to quick onset Start t dabigatran 2 hours prior to the time of the next scheduled dose of the parenteral anticoagulant (e.g. LMWH) or at the time of discontinuation for a continuously administered parenteral drug (e.g. UFH) Dabigatran to parenteral anticoagulant Wait 12 hours (CrCl 30 ml/minute) or 24 hours (CrCl <30 ml/minute) after the last dose of dabigatran before initiating a parenteral anticoagulant Pradaxa Prescribing Information. Jan Lexi-Comp Online. Accessed 3/29/12
28 Rivaroxaban - Warfarin Warfarin to rivaroxaban Discontinue warfarin and initiate rivaroxaban as soon as INR falls to <3.0 (U.S. labeling) Rivaroxaban to warfarin Initiate warfarin and a parenteral anticoagulant 24 hours after discontinuation of rivaroxaban Rivaroxaban affects INR therefore, initial INR measurements after initiating warfarin may be unreliable Rivaroxaban monograph. Lexi-Comp Online. Accessed 3/29/12
29 Rivaroxaban Parenteral Anticoagulants Parenteral anticoagulant to rivaroxaban No bridging therapy necessary due to quick onset Start t rivaroxaban 2 hours prior to the time of the next scheduled dose of the parenteral anticoagulant (e.g. LMWH) or at the time of discontinuation for a continuously administered parenteral drug (e.g. UFH) Rivaroxaban to parenteral anticoagulant Initiate the anticoagulant 24 hours after discontinuation of rivaroxaban Rivaroxaban monograph. Lexi-Comp Online. Accessed 3/29/12
30 Reversing Oral Anticoagulants
31 Reversal ersal Information No antidote/reversal agent available ***Renal function impacts duration of effect*** Allow appropriate time for drug clearance prior to surgical procedures or epidural/spinal i linjections Symptomatic management for bleeding Fluid replacement, hemodynamic support Start measures to support good renal function (fluids, avoiding nephrotoxins, etc) Dialysis removes up to 60% of dabigatran Rivaroxaban - protein binding so no effect ACCP CHEST Guidelines 9 th Ed. CHEST 2012;141:e44S-e88S.
32 Dabigatran and Surgery Renal function Half-life Timing of discontinuation after last (CrCL, ml/min) (hours) dose of dabigatran before surgery Standard risk of bleeding High risk of bleeding >80 13 (11-22) 24 hours 2-4 days >50 to (12-34) 24 hours 2-4days >30 to (13-23) At least 2 days 4 days (48 hours) 30 c 27 (22-35) 2-5 days >5 days Table modified from: van Ryn J, et al. Thromb Haemost 2010;103:
33 High Risk Surgical Procedures (The small print under the table) Includes when complete hemostasis may be required, for example Cardiac surgery, neurosurgery, abdominal surgery or those involving a major organ Other procedures such as spinal anesthesia may also require complete hemostatic function Also consider advancing age, co morbidities (e.g. major cardiac, respiratory or liver disease) and concomitant use of antiplatelet therapy Modified from: van Ryn J, et al. Thromb Haemost 2010;103:
34 Rivaroxaban and Surgery Renal function (CrCL, ml/min) Half-life (hours) Timing of discontinuation after last dose of rivaroxaban before surgery Standard risk of High risk of bleeding bleeding Normal to mild ~9 hours Hold 2 doses Hold 3-4 doses impairment (CrCl >50 ml/min)
35 Life-Threatening Bleeding LIMITED data available to direct therapy Dabigatran Recombinant factor VIIa FEIBA (activated prothrombin complex concentrates or apcc) CHEST guidelines say only if dilutional coagulopathy Rivaroxaban Recombinant factor VIIa PCC was not effective
36 Patient Counseling Pointers
37 Patient Counseling Activity level recommendations are the same as with warfarin Avoid dangerous activities (no sky diving, caution when icy, etc ) Should be taken at same time of day (every 12 hrs or with evening meal) If dose missed, take it as soon as possible but do not double up
38 Patient Counseling Avoid taking NSAIDS or aspirin unless instructed by their healthcare provider Patient should report any adverse effects to provider (bleeding, GI related) Remind any healthcare provider about use of an anticoagulant prior to procedures (dental, surgical) or spinal/epidural catheter placement/removal
39 Dabigatran Pointers Capsules only good dfor 4 months once bottle is opened Blister packs available Instruct patients to swallow the capsules whole Breaking, chewing, or emptying the contents of the capsule can result in increased exposure =3632. Assessed 3/27/12.
40 Rivaroxaban Pointers 10, 15 and 20 mg tablets available 10 and 15 mg tablets are round 20 mg tablets are triangular None are scored Tablets may be crushed and administered via gastric feeding tube May not be given via a NJ, J-tube or GJ tube Xarelto Prescribing Information. December 2011.
41 Important Considerations for Use of New Oral Anticoagulants Much more expensive than warfarin Often patients have much higher insurance copay Compliant patient? Twice daily dosing required for dabigatran Missed doses increase risk of thromboembolism Bleeding risk? No reversal agent is available if bleeding occurs or emergent procedure necessary Mechanical heart valve? Not studied yet
42 Patients in Whom to Consider Use of New Oral Anticoagulants Allergy/intolerance to warfarin Trouble maintaining therapeutic INRs Those without access to monitoring Patients without significant ifi renal or hepatic impairment Patients not on interacting medications Able to be compliant with medications
43 To Wrap It All Up... The new oral anticoagulants are good alternatives to warfarin for patients who need anticoagulation As more agents gain FDA approval, increased use expected Pharmacists will have large role in choice of agents, dosing, adjustment for other disease states, drug interactions & patient education
Essentia Health Med Moment Short Video Tune-Up A brief overview of a new medication, or important new medication information Rivaroxaban (Xarelto ) by Richard Mullvain RPH BCPS (AQC) Current - August 2011
NEWER ANTICOAGULANTS: FOCUS ON STROKE PREVENTION IN ATRIAL FIBRILLATION AND DEEP VEIN THROMBOSIS/PULMONARY EMBOLISM Carol Lee, Pharm.D., Jessica C. Song, M.A., Pharm.D. INTRODUCTION For many years, warfarin
FDA Approved Oral Anticoagulants Generic (Trade Name) Warfarin (Coumadin, Jantoven ) 1 FDA approved indication Prophylaxis and treatment of venous thromboembolism (VTE) Prophylaxis and treatment of thromboembolic
Oral Anticoagulants: What s New? Sallie Young, Pharm.D., BCPS (AQ-Cardiology) Clinical Pharmacy Specialist, Cardiology Penn State Hershey Medical Center firstname.lastname@example.org January 2014 Conflict of Interest
Prescriber Guide 20mg Simply Protecting More Patients 15mg Simply Protecting More Patients 1 Dear Doctor, This prescriber guide was produced by Bayer Israel in cooperation with the Ministry of Health as
Dabigatran (Pradaxa) Guidelines Dabigatran is a new anticoagulant for reducing the risk of stroke in patients with atrial fibrillation. Dabigatran is a direct thrombin inhibitor, similar to warfarin, without
Devang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical Center A.Fib affects 2.2 million Americans. The lifetime
Objectives Atrial Fibrillation and Prevention of Thrombotic Complications: Therapeutic Update Andrea C. Flores Pharm.D Pharmacy Resident at the Miami VA Healthcare System Review the epidemiology, pathophysiology
New oral anticoagulants and antiplatelets: Where do they fit? Meredith Hollinger, PharmD BCPS Clinical Pharmacy Specialist, Cardiology September 2012 Objectives Describe the mechanisms of action for novel
Management for Deep Vein Thrombosis and New Agents Mark Malesker, Pharm.D., FCCP, FCCP, FASHP, BCPS Professor of Pharmacy Practice and Medicine Creighton University 5 th Annual Creighton Cardiovascular
TEGH Family Practice Clinic Day April 4, 03 Use of Anticoagulants in 03: What s New (and What Isn t) Bill Geerts, MD, FRCPC Director, Thromboembolism Program, Sunnybrook HSC Professor of Medicine, University
Mary Bradbury, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Surgery September 18, 2012 Mary.email@example.com This presentation will discuss unlabeled and investigational use of products The author
Update on New Anticoagulants (Apixaban, Dabigatran and Rivaroxaban) Patient Safety Daniel B. DiCola, MD and Paul Ament,, Pharm.D Excela Heath, Latrobe, PA Disclosures: Paul Ament discloses that he receives
Objectives New and Emerging Anticoagulants Adraine Lyles, PharmD, BCPS Clinical Pharmacy Specialist VCU Medical Center Describe the pharmacology of the novel oral anticoagulants Discuss the clinical evidence
Speaker Disclosure Matthew K. Pitlick, Pharm.D., BCPS St. Louis College of Pharmacy/VA St. Louis HCS firstname.lastname@example.org Matthew K. Pitlick, Pharm.D., BCPS declares no conflicts of interest, real or apparent,
MEDICAL ASSISTANCE HBOOK PRI AUTHIZATION OF PHARMACEUTICAL SERVICES I. Requirements for Prior Authorization of Anticoagulants A. Prescriptions That Require Prior Authorization Prescriptions for Anticoagulants
Disclosures The New Oral Anticoagulants: Are they better than Warfarin? Alan P. Agins, Ph.D. does not have any actual or potential conflicts of interest in relation to this CE activity. Alan Agins, Ph.D.
Objectives Just for the RECORD: Rivaroxaban joins the US Anticoagulation Arsenal Anne P. Spencer, PharmD, FCCP, BCPS (AQ Cardiology) Cardiovascular Care Pharmacy Specialist Roper Saint Francis Healthcare
Guideline for the Prescribing of Novel Oral Anticoagulants (NOACs): Dabigatran (Pradaxa ), Rivaroxaban (Xarelto ), Apixaban (Eliquis ) The contents of this CPG are to be used as a guide. Healthcare professionals
New Oral Anticoagulants Tracy Minichiello, MD Associate Professor of Medicine Chief, San FranciscoVA Anticoagulation and Thrombosis Service Ansell, J. Hematology Copyright 2010 American Society of Hematology.
Analyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation Drew Baldwin, MD Virginia Mason Seattle, Washington NCVH May 29,
New Oral Anticoagulants in the Management of Atrial Fibrillation June, 2012 By Deborah K Brokaw, Pharm.D. Introduction Since the 1950 s, the only orally available anticoagulant has been the vitamin K antagonist
NEW ORAL ANTICOAGULANTS: WHAT EVERY PHARMACIST SHOULD KNOW LORI B. HORNSBY, PHARMD, BCPS ASSOCIATE CLINICAL PROFESSOR AUHSOP CLINICAL PHARMACIST MIDTOWN MEDICAL CENTER OUTPATIENT CLINIC COLUMBUS, GEORGIA
MEDICAL ASSISTANCE HBOOK I. Requirements for Prior Authorization of Anticoagulants A. Prescriptions That Require Prior Authorization Prescriptions for Anticoagulants which meet any of the following conditions
~~Marshfield Labs Presents~~ Laboratory Monitoring of Anticoagulant Therapy Session 3 of 4 Michael J. Sanfelippo, M.S. Technical Director, Coagulation Services Session 3 Topics Direct Thrombin Inhibitors:
New Oral Anticoagulants How safe are they outside the trials? Objectives The need for anticoagulant therapy Indications for anticoagulation Traditional anticoagulant therapies Properties of new oral anticoagulants
New Antithrombotic Agents DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau - None Consultant Amgen Tom DeLoughery, MD FACP FAWM Oregon Health and Sciences University What I am Talking About
NnEeWw DdEeVvEeLlOoPpMmEeNnTtSs IiıNn OoRrAaLl AaNnTtIiıCcOoAaGgUuLlAaTtIiıOoNn AaNnDd RrEeVvEeRrSsAaLl Mikele Wissing, RN June 2014 Introduction until recently, was the unrivaled medication for treatment
This policy has been developed through review of medical literature, consideration of medical necessity, generally accepted medical practice standards, and approved by the IEHP Pharmacy and Therapeutics
+ New oral anticoagulants: A review of current indications November 2 nd, 2012 Dr. Sudeep Shivakumar, Hematology Dalhousie University + Objectives es To review indications for anticoagulation To discuss
Experience matters: Practical management in your hospital Dr AGG Turpie McMaster University, Hamilton, ON, Canada Disclosures AGG Turpie has acted as a consultant for Bayer HealthCare, Janssen, Sanofi-Aventis,
To Clot or Not What s New In Anticoagulation? Anita Ralstin, MS CNS CNP 1 Clotting Cascade 2 Anticoagulant drug targets Heparin XI VIII IX V X VII LMWH II Warfarin Fibrin clot 1 Who Needs Anticoagulation
Key Points to consider when prescribing NOACs Introduction Three new/novel oral anticoagulants (NOAC) have been licensed in Ireland since 2008: Dabigatran Etexilate (Pradaxa ) 75mg, 110mg, 150mg. Rivaroxaban
Dabigatran and Rivaroxaban: Challenges in the Perioperative Setting Claudia Swenson, Pharm.D., CDE, BC-ADM, FASHP Central Washington Hospital Wenatchee, WA email@example.com Dabigatran and Rivaroxaban:
COMPARISON OF NEW ORAL ANTICOAGULANTS AND FREQUENTLY- ASKED QUESTIONS FROM PATIENTS AND PHYSICIANS TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVES: To provide a comparison of the new
Page 1 of 9 ANALYTE NAME AND STRUCTURE - RIVAROXABAN SYNONYMS Xarelto CATEGORY Anticoagulant TEST CODE PURPOSE Therapeutic Drug Monitoring GENERAL RELEVANCY BACKGROUND Xarelto (rivaroxaban) is an orally
Novel Anticoagulation Agents DISCLOSURES James W. Haynes, MD Department of Family Medicine Univ of TN Health Science Center (Chattanooga) Objectives Understand mechanism of action behind the NOAC agents
DEEP VEIN THROMBOSIS (DVT): TREATMENT OBJECTIVE: To provide an evidence based approach to treatment of patients presenting with deep vein thrombosis (DVT). BACKGROUND: An estimated 45,000 patients in Canada
Comparative Anticoagulation Laurajo Ryan, PharmD, MSc, BCPS, CDE Clinical Associate Professor The University of Texas at Austin College of Pharmacy The University of Texas Health Science Center Pharmacotherapy
ISSUE DATE June 22, 2015 SUBJECT EFFECTIVE DATE MEDICAL ASSISTANCE BULLETIN NUMBER *See below BY Prior Authorization of Anticoagulants Pharmacy Service Leesa M. Allen, Deputy Secretary Office of Medical
Venous Thromboembolism: Long Term Anticoagulation Dan Johnson, Pharm.D. Disclosures No financial relationships with products discussed Off-label use of drug therapy always discussed Objectives Review clinical
Antiplatelet and Antithrombotic Therapy Dr Curry Grant Stroke Prevention Clinic Quinte Health Care Disclosure of Potential for Conflict of Interest Dr. F.C. Grant Atrial Fibrillation FINANCIAL DISCLOSURE:
Reversing the New Anticoagulants Disclosure Susan C. Lambe, MD Assistant Clinical Professor Department of Emergency Medicine University of California, San Francisco Roadmap for today 1 Roadmap for today
Winship Cancer Institute of Emory University New Anticoagulants: When and Why Should I Use Them? Christine L. Kempton, MD, MSc Associate Professor of Pediatrics and Hematology and Medical Oncology Hemophilia
The New Anticoagulants are Here! Do you know how to use them? Arrhythmia Winter School February 11 th, 2012 Jeff Healey RELY: A New Era in AF Connolly SJ et al. N Engl J Med 2009;361:1139-1151 ROCKET-AF:
MCHENRY WESTERN LAKE COUNTY EMS SYSTEM OPTIONAL CE ADVANCED LEVEL (EMTP, PHRN, ECRN) August 2013 Anticoagulants Anticoagulants are agents that prevent the formation of blood clots. Before we can talk about
NHS FORTH VALLEY RIVAROXABAN AS TREATMENT FOR DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM IN ADULTS Date of First Issue 01/12/ 2012 Approved 15/11/2012 Current Issue Date 29/10/2014 Review Date 29/10/2016
New Anticoagulants for the Treatment of Thromboembolism With a little subplot on superficial thrombophlebitis Mark Crowther 1 Disclosures Advisory Boards in last 24 months Pfizer, Alexion, Bayer, CSL Behring,
Dabigatran (Pradaxa) 1 Dabigatran (Pradaxa) for stroke prevention in patients with non-valvular atrial fibrillation (da-big-a-tran) Similar rate of major bleeding to warfarin KEY POINTS Dabigatran is an
Xabans Good for What Ails Ya? Brian Tiffany, MD, PhD, FACEP Dept of Emergency Medicine Chandler Regional Medical Center Mercy Gilbert Medical Center DISCLOSURES No relevant financial disclosures I will
The New Kids on the Block: Oral Anticoagulants Lauren E. Odum, PharmD, BCPS Clinical Assistant Professor UMKC School of Pharmacy at MU April 11, 2014 Objectives Be able to Understand the major trials leading
Name: generic (trade) Rivaroxaban (Xarelto ) HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below What it is Indications
New Developments in Oral Anticoagulants: Treating and Preventing Embolic Events in the 21 st Century David Stewart, PharmD, BCPS Associate Professor of Pharmacy Practice East Tennessee State University
Dabigatran for stroke prevention in Atrial Fibrillation Clinical Guideline NICE TA249 published in March 2012 recommended dabigatran (Pradaxa ) as an option for the prevention of stroke and systemic embolism
East Kent Prescribing Group Rivaroxaban (Xarelto ) Safety Information Approved by the East Kent Prescribing Group. Approved by: East Kent Prescribing Group (Representing Ashford CCG, Canterbury and Coastal
Novel Anticoagulants Kathleen Ozsvath, MD Associate Professor of Surgery, Albany Medical Center Partner, The Vascular Group, Albany, NY Chief of Vascular Services, Samaritan and St. Mary s Hospital, Troy,
Anticoagulation Strategies: How to Integrate the New Anticoagulants into Your Practice Virginia Association of Hematology & Oncology Spring Meeting April 18, 2015 B. Gail Macik, MD Professor of Medicine
Anticoagulation and Reversal John Howard, PharmD, BCPS Clinical Pharmacist Internal Medicine Affiliate Associate Clinical Professor South Carolina College of Pharmacy Disclosures I have no Financial, Industry,
New Anticoagulants: Are we Ready to Replace Warfarin? Carole Goodine, RPh Horizon Health Network Stroke Conference 2011 Warfarin Decreases stroke risk by 60-70% Superior to ASA and ASA plus clopidogrel
Kevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013 Family physician with Rivergrove Medical Clinic Practice in the north end since 1985 Medical Director of the Wellness
P a g e 1 Dorset Cardiac Centre Patients with Atrial Fibrillation/Flutter undergoing DC Cardioversion or Ablation procedures- Guidelines for Novel Oral Anti-coagulants (NOACS) licensed for this use February
Medication Policy Manual Policy No: dru361 Topic: Pradaxa, dabigatran Date of Origin: September 12, 2014 Committee Approval Date: September 12, 2014 Next Review Date: September 2015 Effective Date: November
Outpatient Treatment of Deep Vein Thrombosis with Low Molecular Weight Heparin (LMWH) Clinical Practice Guideline August 2015 General Principles: There is compelling data in the medical literature to support
What s in a name? Practical aspects of using DOACs (Direct Oral Anticoagulants) James L. Sebastian, MD, MACP Professor of Medicine (GIM) Medical College of Wisconsin February 5, 2016 DOAC NOAC NOAC ODI
Thrombosis management: A time for change practical management with NOACs Dr Wala Elizabeth Medical Director, Bayer Healthcare Kenya Association of Physicians Conference 10 th May 2013 New anticoagulants:
APPENDIX F WORKING IN PARTNERSHIP WITH Information sheet Dabigatran (Pradaxa )110mg and 150mg Tablets FOR STROKE PREVENTION IN ATRIAL FIBRILLATION Surrey Prescribing Clinical Network classification: Green
NHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation Date of First Issue 06/06/2012 Approved 06/06/2012 Current Issue Date 29/10/2014 Review Date 29/10/2016 Version 1.4 EQIA Yes 01/06/2012
ANTICOAGULATION UPDATE C AR R I E P AL M E R, D N P, RN, AN P - BC OBJECTIVES At the end of the presentation, the NP will be able to: Identify new indications for target-specific oral anticoagulants (TSOACs),
Novel Anticoagulants in the Elderly Bahar Matusik, PharmD, BCPS Assistant Professor Department of Pharmacy Practice & Administration University of Saint Joseph, School of Pharmacy Disclosures Dr. Bahar
Making Sense of the Newer Anticoagulants Brian Tiffany, MD, PhD, FACEP Dept of Emergency Medicine Chandler Regional Medical Center Mercy Gilbert Medical Center I M FROM ARIZONA! DISCLOSURES No relevant
XARELTO (RIVAROXABAN) PRESCRIBER GUIDE Prescribing information found on pages 16-17 This guide is to be used to support the appropriate use of Xarelto in the following indications: Prevention of stroke
Implementation of NICE TA 261 Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism Contents 1. Executive summary 2. Introduction
Deniz Yavas, PharmD PGY-2 Ambulatory Care Pharmacy Resident Detroit Veterans Affairs Medical Center } Most common arrhythmia 0.4-1% of Americans (2.2 mil people) 1,2 } Incidence increases with age 6% (65
Anticoagulation Strategies: Are New Oral Anticoagulants Ready for Prime Time? Virginia American College of Physicians Annual Conference March 7, 2014 B. Gail Macik, MD Professor of Medicine & Pathology
STARTING, SWITCHING OR STOPPING NEW ORAL ANTICOAGULANTS: A Practical Approach Jeffrey I Weitz, MD, FRCP(C), FACP Professor of Medicine and Biochemistry McMaster University Canada Research Chair in Thrombosis
QUICK REFERENCE Clinical Practice Guide on Antithrombotic Drug Dosing and Management of Antithrombotic Drug- Associated Bleeding Complications in Adults February 2014* Mary Cushman 1 Wendy Lim 2 Neil A
The 2 nd World Congress on CONTROVERSIES IN HEMATOLOGY (COHEM) Barcelona, Spain September 6 8, 2012 New anticoagulants: Monitoring or not Monitoring? Not Monitoring Anna Falanga, MD Immunohematology and
New Agents for Treatment of DVT Disclosure PI Adopt and Amplify trials Mark Oliver, MD, RVT, RPVI,FSVU BMS and Pfizer Speaker VTE Venous Thromboembolism Recognized DVT s New : 170,000 Recurrent : 90,000